Moderna takes axe to '24 sales guidance, sending shares lower

The post-pandemic period has posed serious challenges for financial forecasters at the top mRNA vaccine makers, as evidenced by Pfizer's inability to hit its original sales outlook for 2023.

But these forecasting challenges are still dragging on into 2024. Take Moderna, which just chopped $500 million to $1 billion from its 2024 sales forecast—in August—leaving some investors rushing to sell shares.